Ibett is a Project Manager at Pharm-Olam, with over 13 years of experience in oncology-related research, including work on clinical trials that have contributed to FDA approvals in the oncology setting. With a background in site management, Ibett has the ability to assess clinical trials from the physician and site staff perspective, in an effort to make processes associated with clinical trials as efficient as possible for both the site and the patient. Impacted by cancer within her family, Ibett brings passion to her work with clinical trials, with the goal of connecting those who have embarked on their cancer journey, with innovative and new treatments. When Ibett is not at work, Ibett divides her time between earning her Masters of Science in Organizational Leadership, trying new food from around the globe, and traveling with her husband.
March 19th, 2020
Pharm-Olam is a mid-sized, global CRO that provides clinical research solutions for rare diseases, oncology, hematology, autoimmune conditions, allergies, and infectious diseases. Our organization was hired to support a Phase I, first-in-human study of a programmed cell death receptor (PD-1) inhibitor monoclonal antibody (mAb) drug treatment for solid tumor malignancies. The research is in its final stages. Pharm-Olam is proud to have supported this critical research, the patients and the sponsor involved.